Navigation Links
Rigel to Present at Collins Stewart Growth Conference
Date:7/3/2008

SAN FRANCISCO, July 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, Rigel's executive vice president and chief operating officer, will present a company overview at the Fourth Annual Collins Stewart Growth Conference on Tuesday, July 8, 2008 at 11:30 a.m. EDT at The Mandarin Oriental Hotel in New York City.

To access the live audio webcast or the subsequent archived recording, log on to http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

Contact: Ryan Maynard

Phone: 650.624.1284

Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Rigel Announces First Quarter 2008 Financial Results
2. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
3. Rigel Announces Participation in Upcoming Investor and Partnering Conferences
4. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
5. Rigel Announces Offering of 4,000,000 Shares of Common Stock
6. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
7. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
8. Rigel Announces Third Quarter 2007 Financial Results
9. Nu Skin Enterprises to Present at Oppenheimer Consumer Growth Conference
10. FGX International to Present at the Oppenheimer 8th Annual Consumer Growth Conference
11. SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Heska Announces Extension of Credit Agreement With Wells Fargo 2Heska Announces Extension of Credit Agreement With Wells Fargo 3Prodigy AutoCode Now Available in 116 Harris Teeter Pharmacies 56299 1Prodigy AutoCode Now Available in 116 Harris Teeter Pharmacies 56299 2Onyx Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 13865 1Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 1Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 2Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 3
Other Medicine Technology:Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 2Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 3Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 4Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 5Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 3Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 4Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 5